✦ LIBER ✦

A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy

✍ Scribed by Dr Marinos C. Dalakas; Richard H. Quarles; Robert G. Farrer; James Dambrosia; Shawke Soueidan; Daniel P. Stein; Edward Cupler; Elizabeth A. Sekul; Carlos Otero

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 401 KB
Volume: 40
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410400516

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Experience of intravenous immunoglobulin

Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study

✍ Stéphanie Rist; Jérémie Sellam; Eric Hachulla; Christelle Sordet; Xavier Puéchal 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 104 KB 👁 2 views

Results and long-term followup of intrav

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients

✍ P. Cherin; S. Pelletier; A. Teixeira; P. Laforet; T. Genereau; A. Simon; T. Mais 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

The antiosteoporotic efficacy of intrave

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade : A double blind, randomized, placebo-controlled crossover study

✍ Terrence H. Diamond; Julie Winters; Angie Smith; Paul De Souza; John H. Kersley; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## BACKGROUND. Prostate carcinoma therapy with combined androgen blockade may result in high bone-turnover with significant bone loss. This study was undertaken to evaluate the antiosteoporotic efficacy of intravenous pamidronate in a double blind, randomized, placebo-controlled, crossover study.

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views